Jeong Il Yu1, Doo Ho Choi2, Seung Jae Huh1, Eun Yoon Cho3, Kyubo Kim4, Eui Kyu Chie4, Sung W Ha4, In Ae Park5, Sung Ja Ahn6, Ji Shin Lee7, Kyung Hwan Shin8, Youngmee Kwon8, Yong Bae Kim9, Chang-Ok Suh9, Ja Seung Koo10, Jin Hee Kim11, Bae Gwon Jeong12, In Ah Kim13, Jong Hoon Lee14, Won Park1. 1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: doho.choi@samsung.com. 3. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. 5. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea. 7. Department of Pathology, Chonnam National University Medical School, Gwangju, Korea. 8. Center of Breast Cancer, National Cancer Center, Goyang, Korea. 9. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. 10. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. 11. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. 12. Department of Radiation Oncology, Gyeongsang Institute of Health Sciences, Jinju, Korea. 13. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea. 14. Department of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.
Abstract
PURPOSE: We designed the present study to investigate differences in prognostic factors and failure patterns between patients with invasive micropapillary carcinoma or carcinoma with micropapillary component (IMPC) and randomly matched patients with invasive ductal carcinoma (IDC) of the breast at multiple institutions of the Korean Radiation Oncology Group (KROG). MATERIALS AND METHODS: This retrospective multicenter study was performed using subjects treated from January 1999 to November 2011. Female patients who had undergone curative resection for breast cancer withoutneoadjuvant chemotherapy were considered for this study. Exact matches were made for age (± 3 years), pathologic tumor and node stage, treatment method (surgery with or without radiotherapy), and period when surgery was performed (within 1 year) at the same institution. RESULTS:A total of 534 patients were analyzed. The median follow-up period was 59 months in both groups. In the comparison of clinicopathologic characteristics, rates of lymphovascular invasion (LVI) and nuclear grade III were both significantly higher in IMPC than in IDC (P < .001, P = .01, respectively). During the follow-up period, recurrences developed in 40 patients with IMPC (15.0%) and 21 with IDC (7.9%). Locoregional recurrence (LRR) developed in 22 patients with IMPC (8.2%) and 10 with IDC (3.7%). The rate of distant metastasis did not differ between the 2 groups (P = .52). LRR-free survival (P = .03) and recurrence-free survival (P = .007) were significantly different between the 2 groups, but overall survival was not (P = .67). CONCLUSION:IMPC is associated with a higher rate of LVI, high nuclear grade, and a propensity for LRR compared to IDC. Modification of the locoregional treatment modality might be needed in this pathologic subtype of breast cancer.
RCT Entities:
PURPOSE: We designed the present study to investigate differences in prognostic factors and failure patterns between patients with invasive micropapillary carcinoma or carcinoma with micropapillary component (IMPC) and randomly matched patients with invasive ductal carcinoma (IDC) of the breast at multiple institutions of the Korean Radiation Oncology Group (KROG). MATERIALS AND METHODS: This retrospective multicenter study was performed using subjects treated from January 1999 to November 2011. Female patients who had undergone curative resection for breast cancer without neoadjuvant chemotherapy were considered for this study. Exact matches were made for age (± 3 years), pathologic tumor and node stage, treatment method (surgery with or without radiotherapy), and period when surgery was performed (within 1 year) at the same institution. RESULTS: A total of 534 patients were analyzed. The median follow-up period was 59 months in both groups. In the comparison of clinicopathologic characteristics, rates of lymphovascular invasion (LVI) and nuclear grade III were both significantly higher in IMPC than in IDC (P < .001, P = .01, respectively). During the follow-up period, recurrences developed in 40 patients with IMPC (15.0%) and 21 with IDC (7.9%). Locoregional recurrence (LRR) developed in 22 patients with IMPC (8.2%) and 10 with IDC (3.7%). The rate of distant metastasis did not differ between the 2 groups (P = .52). LRR-free survival (P = .03) and recurrence-free survival (P = .007) were significantly different between the 2 groups, but overall survival was not (P = .67). CONCLUSION: IMPC is associated with a higher rate of LVI, high nuclear grade, and a propensity for LRR compared to IDC. Modification of the locoregional treatment modality might be needed in this pathologic subtype of breast cancer.
Authors: Gary D Lewis; Yan Xing; Waqar Haque; Tejal Patel; Mary Schwartz; Albert Chen; Andrew Farach; Sandra S Hatch; E Brian Butler; Jenny Chang; Bin S Teh Journal: Cancer Commun (Lond) Date: 2019-10-21